Oily Skin: When to See a Doctor
Learn why your skin is oily, what causes excess sebum production, and when oily skin signals something that needs medical attention. Reviewed by board-certified physicians.
Ozempic Butt: Drugs That Cause It and Treatments That Help
Which medications cause ozempic butt, why GLP-1 drugs lead to gluteal volume loss, and the pharmacologic and procedural treatments that can restore shape and skin quality.
Painful Urination: Drugs That Cause It and Medications That Treat It
A clinical guide to dysuria covering the prescription drugs most likely to cause painful urination, the medications used to treat it, diagnostic steps, and when to seek medical care.
Pale Stool: When to See a Doctor
Learn what causes pale or clay-colored stool, when pale stool signals a serious problem like bile duct obstruction, and exactly when to see a doctor for evaluation and treatment.
Palpitations: What Could Be Causing Them
A guide to the causes, diagnosis, and treatment of heart palpitations, including when to seek emergency care and which tests your doctor may order.
Peptide-Related Flushing: A Differential and Emergency Triage Map
Evidence-led flushing triage for bremelanotide, CJC-1295 and research peptides, separating documented effects, unknown rates, allergy, and other causes.
Peptide Flushing: When to See a Doctor
Peptide flushing is common with GHRPs, BPC-157, and PT-141. Learn the causes, how to tell benign flushing from a warning sign, and when to seek medical evaluation.
Peptide Numbness: What Could Be Causing It
Peptide therapy can cause numbness and tingling through several mechanisms. Learn the differential diagnosis, when to seek help, and how clinicians evaluate peptide-related paresthesias.
Weight Loss Plateau: Drugs That Cause It and Medications That Break Through It
A guide to medications that trigger weight loss plateaus and pharmacologic strategies (GLP-1 agonists, metformin, combination therapy) proven to restart stalled progress.
Reflux Causes: GERD, Hernia, Meds and More
Reflux often stems from GERD, hiatal hernia, or slow gastric emptying. Learn key causes, diagnosis steps, and when symptoms warrant a doctor visit.
Salt Cravings: Labs, Causes, and Next Steps
Persistent salt cravings can signal adrenal insufficiency, electrolyte imbalance, or dehydration. Learn which labs to request, what causes salt cravings, and when to see a doctor.
Sleep Apnea Symptoms: Labs, Diagnosis, and Next Steps
Recognize the warning signs of sleep apnea, understand which labs and tests confirm the diagnosis, and learn the evidence-based next steps for treatment.
SSRI Discontinuation Symptoms: Labs, Diagnosis, and Next Steps
A clinical guide to SSRI discontinuation syndrome covering symptoms, diagnostic workup, lab tests to rule out mimics, tapering protocols, and when to seek urgent care.
Sulfur Burps: Drugs That Cause or Treat Them
Understand medication-related belching, sulfur-smelling burps, common remedies, symptom tracking and when to contact your prescribing team.
Sweating Reduced: Labs, Diagnosis, and Next Steps
Reduced sweating (hypohidrosis) can signal nerve damage, medication side effects, or autonomic dysfunction. Learn which labs to request, how doctors diagnose it, and what treatment options exist.
Tendinitis: What Could Be Causing It and When to Seek Treatment
A clinical guide to the causes of tendinitis, including overuse, systemic disease, medications, and aging. Covers diagnosis, treatment options, and when to worry about tendon pain.
Trouble Falling Asleep: Labs, Diagnosis, and Next Steps
Learn what labs to request, how sleep-onset insomnia is diagnosed, and the evidence-based next steps when you consistently have trouble falling asleep.
Unexplained Fever: Labs and Next Steps
A clinical guide to unexplained fever workup, including which labs to order, imaging options, when to worry, and evidence-based next steps for fever of unknown origin (FUO).
Weight Gain Labs and Next Steps: The Complete Diagnostic and Treatment Guide
Learn which lab tests to request when you experience unexplained weight gain, what the results mean, and evidence-based next steps including medications, lifestyle changes, and specialist referrals.
White Spots on Nails: Labs, Causes, and Next Steps
Learn what causes white spots on your nails, which lab tests to request, when to worry, and evidence-based treatment options. prepared by the HealthRX.com Editorial Team.
Yellow Eyes: What Could Be Causing It and When to See a Doctor
Yellow eyes signal elevated bilirubin levels. Learn the medical causes of scleral icterus, from liver disease to hemolytic anemia, how doctors diagnose it, and which treatments work.
Tadalafil (Generic) Safety for Older Adults (50-64): Dosing, Risks, and Monitoring
Evidence-based safety guide for generic tadalafil (2.5-20 mg) in adults aged 50-64, covering cardiovascular risks, drug interactions, dose adjustments, and monitoring protocols.
How to Safely Stop TB-500: A Clinician-Guided Discontinuation Protocol
Evidence-based guide to tapering and discontinuing TB-500 (thymosin beta-4 active fragment), including taper schedules, monitoring parameters, and what to expect after stopping.
Egrifta (Tesamorelin) Complete Drug-Drug Interaction Profile
A clinician-grade review of tesamorelin (Egrifta) drug-drug interactions, covering antiretrovirals, cortisol-modulating agents, insulin, and growth hormone axis drugs with cited evidence.
Egrifta (Tesamorelin) Off-Label Uses: Evidence Levels for Every Indication
A guide to tesamorelin off-label uses beyond HIV lipodystrophy, including evidence levels for cognitive decline, NAFLD, body composition, and more.
Tesamorelin Overdose: A Product-and-Exposure Triage Record
What to do after accidental tesamorelin excess: emergency triage, product identity, known label risks, and the lack of a validated toxic-dose threshold.
Tesamorelin (Egrifta) Pharmacogenomics: How Genetic Variability Affects Response
Evidence-based review of tesamorelin pharmacogenomics, including GHRH receptor polymorphisms, GH1 variants, CYP metabolism considerations, and how genetic variability influences Egrifta efficacy in HIV-associated lipodystrophy.
Egrifta (Tesamorelin) Safety in Young Adults (18 to 29): What Clinicians and Patients Should Know
A clinical guide to tesamorelin (Egrifta) safety in young adults aged 18 to 29, covering side effects, monitoring, fertility considerations, and long-term use data for HIV-associated lipodystrophy.
Testosterone Cypionate Dosing for Adults Aged 30 to 49: Evidence-Based Guide
Complete guide to testosterone cypionate dosing for adults aged 30 to 49, including starting doses, titration schedules, injection frequency, monitoring labs, and dose adjustments based on clinical guidelines and trial data.
Testosterone Cypionate Cost vs. Alternatives: A Full Comparison of TRT Options
Compare testosterone cypionate pricing, efficacy, and side-effect profiles against enanthate, undecanoate (Aveed), topical gels (AndroGel), patches, and oral jatenzo. Includes real-world cost data, trial evidence, and switching guidance.
Testosterone Cypionate Future Formulations & Pipeline
A clinical overview of next-generation testosterone cypionate delivery systems, novel formulations in development, and pipeline compounds that may reshape TRT protocols.
Testosterone Cypionate Off-Label Uses With Evidence Levels
A guide to testosterone cypionate off-label applications, from female sexual dysfunction to sarcopenia, with trial-level evidence ratings for each use.
Testosterone Cypionate Self-Injection: Route, Supplies and Lab Timing
Prepare for prescribed testosterone cypionate injections with route checks, supply guidance, vial handling, dose-volume math and lab timing.
Testosterone Enanthate Safety in Young Adults (18-29): What the Evidence Shows
Evidence-based safety profile of testosterone enanthate in young adults aged 18-29, covering fertility risks, cardiovascular monitoring, hematocrit thresholds, and clinical guidelines for safe prescribing.
Thymosin Alpha-1 Regulatory Status: US, EU, Canada, and UK
A country-by-country breakdown of thymosin alpha-1 (thymalfasin) regulatory status, covering FDA positioning, EMA review history, Health Canada classification, and MHRA standing.
Thymosin Alpha-1 Safety Signals and FDA Actions: What Patients and Clinicians Need to Know
A clinical review of thymosin alpha-1 (thymalfasin) safety signals, FDA regulatory actions, adverse event reports, and what the evidence says about long-term risk.
Thymosin Alpha-1 Young Adult (18 to 29) Dosing: What the Evidence Supports
Evidence-based dosing guide for thymosin alpha-1 (thymalfasin) in young adults aged 18 to 29, covering standard protocols, administration technique, monitoring, and clinical considerations.
Thymosin Alpha-1 Young Adult (18 to 29) Monitoring: Lab Schedule, Safety Checks, and What to Track
Complete monitoring guide for thymosin alpha-1 (thymalfasin) in young adults aged 18 to 29. Covers baseline labs, follow-up intervals, immune markers, fertility considerations, and when to adjust or stop therapy.
How to Know Which Diet Is Best for My Body Type
Body-type dieting lacks clinical evidence. Learn what actually predicts dietary success, including thyroid function, insulin sensitivity, and metabolic markers, plus how to match your eating pattern to your biology.
How to Read Your Hormone Lab Results: A Patient's Guide
Learn how to interpret TSH, free T4, free T3, testosterone, estradiol, and other hormone lab values. Understand reference ranges, optimal zones, and when results signal a need for treatment.
What Are the Key Safety Warnings for Zepbound (Tirzepatide)?
A guide to every major safety warning for Zepbound (tirzepatide), including the boxed warning for thyroid C-cell tumors, pancreatitis risk, gallbladder events, and renal injury.
What Is Zepbound (Tirzepatide)? Eli Lilly's Weight Loss Injection Explained
Zepbound (tirzepatide) is a dual GIP/GLP-1 receptor agonist approved for chronic weight management. Learn about dosing, clinical trial results, side effects, cost, and how it compares to semaglutide.
Which Labs Are Needed Before My Doctor Visit?
A complete guide to the blood tests and lab panels your doctor may order before a metabolic health, weight management, or hormone therapy appointment, including thyroid, lipid, glucose, and hormone panels.
What Causes Hot Flashes? What Supplements Can Help? HRT Explained
Hot flashes affect up to 80% of menopausal women. Learn the science behind vasomotor symptoms, which supplements have clinical evidence, and how hormone replacement therapy works.
Alprostadil (Caverject/MUSE) Accelerated Titration: Dosing, Safety, and Clinical Protocols
Evidence-based guide to accelerated alprostadil titration for erectile dysfunction, covering Caverject intracavernosal injection and MUSE urethral suppository dose escalation schedules, safety monitoring, and real-world protocols.
AOD-9604 Max-Dose Rationale: Titration Ceiling, Evidence Limits, and What Comes After
Clinical review of AOD-9604 (HGH fragment 176-191) maximum dosing, dose-escalation protocols, and the evidence basis for upper titration limits in fat-loss peptide therapy.
AOD-9604 Slow Titration for Sensitivity: How to Escalate Doses Safely
A guide to slow titration of AOD-9604 (HGH fragment 176-191) for patients with peptide sensitivity, covering starting doses, escalation schedules, and monitoring benchmarks.
Armour Thyroid Re-Titration After Stopping: How to Restart Natural Desiccated Thyroid Safely
Evidence-based guide to re-titrating Armour Thyroid after a treatment gap. Covers starting doses, escalation schedules, lab monitoring, and when to expect symptom relief.
BPC-157 Titration: What Dose-Escalation Claims Leave Unanswered
A close look at BPC-157 fast-titration claims, dose-response research, and why animal experiments do not establish a human escalation schedule.
BPC-157 Slow Titration for Sensitivity: How to Escalate Doses Safely
A guide to slow BPC-157 pentadecapeptide titration for patients with sensitivity. Covers dose escalation schedules, monitoring, and when to hold or advance.
CJC-1295 Max-Dose Rationale: How High Can You Safely Titrate?
Evidence-based guide to CJC-1295 (modified GRF 1-29) dose escalation, maximum dose ceilings, and the clinical rationale behind titration protocols for growth hormone optimization.
Farxiga Max-Dose Use and Beyond: Dapagliflozin Titration Guide
Evidence-based guide to dapagliflozin (Farxiga) dose escalation, max-dose rationale from DAPA-HF and DECLARE-TIMI 58, and clinical considerations for 10 mg ceiling dosing.
Avodart Slow Titration for Sensitivity: How to Dose-Escalate Dutasteride Safely
Evidence-based guide to slow titration of dutasteride (Avodart) for patients with drug sensitivity. Covers dose escalation schedules, monitoring, and managing side effects during up-titration.
Enclomiphene Citrate Re-Titration After Stopping: How to Restart Safely
Evidence-based guide to re-titrating enclomiphene citrate after a treatment break. Covers dose escalation schedules, monitoring labs, and clinical decision points for restarting therapy.
Enclomiphene Citrate Slow Titration for Sensitivity
How to titrate enclomiphene citrate slowly for patients with estrogen-receptor sensitivity, including starting doses, escalation timelines, monitoring labs, and when to hold at a plateau.
Epitalon Standard Titration Schedule
Evidence-based guide to Epitalon tetrapeptide dose escalation, cycle length, and monitoring. Covers standard titration protocols, timing, and what limited clinical data supports.
Oral Estradiol Standard Titration Schedule
Evidence-based guide to oral estradiol dose escalation for menopausal hormone therapy, including starting doses, titration intervals, monitoring labs, and target serum levels.
Finasteride Max Dose: Rationale, Titration, and What the Evidence Says About Going Higher
A clinical breakdown of finasteride dosing from 1 mg to 5 mg and beyond, covering dose-response pharmacology, titration protocols, and why higher doses rarely yield proportional benefit.
GHK-Cu Managing Efficacy Plateau: Titration, Dose Escalation, and Cycling Strategies
Evidence-based strategies for managing GHK-Cu efficacy plateaus, including dose escalation protocols, cycling schedules, and adjunct approaches to restore copper tripeptide responsiveness.
Leqvio Dosing: 284 mg Schedule and No Titration Needed
Leqvio has one FDA-approved dose, 284 mg by subcutaneous injection, given at day 1, month 3, then every 6 months. There is no dose titration.